DigestRedComo funciona
Red
/
Empresas
Pu
No verificado

PureTech Health plc

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

48 Comunicados de prensa

Ver todos los comunicados de prensa
06/01/2026
Biotecnología
Farmacéutica
Salud
Eventos
Web y redes sociales
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
18/12/2025
PureTech Appoints Robert Lyne as Chief Executive Officer
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
08/12/2025
Multimedia
Higiene alimentaria
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
05/12/2025
Multimedia
Industria
Eventos
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
03/11/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
22/10/2025
Ciencia
Tercera edad
Biotecnología
Farmacéutica
Salud
Ir de compras
Medicina - Varios
Industria
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
29/09/2025
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
11/09/2025
Psiquiatría
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
28/08/2025
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Mercado de valores
PureTech Health plc – Half-Year Report
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0
21/08/2025
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Eventos
Industria
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
Fuente
PureTech Health plc
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0